News & Events

Learn about what's new with CMC Biologics

CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy


Seattle, Wash., New York, N.Y. and Copenhagen, Denmark – July 29, 2015 – CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave’s Orbitopathy and other indications.

Follow Us
Join us on LinkedIn Follow us on Twitter